AI Frontier Post
Get the Briefing
AI News

Isomorphic Labs in funding talks at a $40B valuation: AI drug design gets a pharma-scale price tag

Alphabet-backed Isomorphic Labs is in early talks to raise new funding at a valuation of at least $40 billion, Bloomberg reports — potentially $50 billion — just five months after its $2.1 billion Series B. The proposed price tests whether investors believe AI-designed drugs can survive contact with the clinic.

MD Marcus Doyle Senior Technology Writer · October 8, 2026 · 5 min read

The talks are early, and the financing has not closed. Bloomberg reports that Isomorphic Labs — the AI drug-discovery company founded by DeepMind CEO Demis Hassabis — is in discussions to raise new funding at a valuation of at least $40 billion, according to people familiar with the effort. One person told Bloomberg the figure could reach $50 billion, though the terms could still change. The report does not identify investors in the talks or say how much Isomorphic is seeking to raise.

Five months after $2.1 billion

The new talks land strikingly soon after the company's last round. In May 2026, Isomorphic Labs raised a $2.1 billion Series B led by Thrive Capital, with participation from Alphabet and GV alongside new backers MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. That followed a $600 million external round in March 2025, also led by Thrive Capital, with GV and Alphabet participating.

Illustration of a neural network generating candidate drug molecules against a protein target structure.
From prediction to candidates: Isomorphic Labs says its engine designs molecules computationally before lab testing. Graphic: AI Frontier Post.

The AlphaFold inheritance

Isomorphic Labs was formed in 2021 as a spinout of Google DeepMind, with Hassabis building it around AlphaFold's breakthrough in predicting protein structures. The company has since pushed beyond prediction toward a full drug-design engine: it announced collaborations with Eli Lilly and Novartis in 2024 — which the company said could be worth nearly $3 billion in upfront and milestone payments — and later expanded its Novartis work and added a research partnership with Johnson & Johnson.

Illustration of a digital laboratory flask with rising capital-flow charts, representing the $40 billion funding talks.
A pharma-scale price tag for a company with no marketed medicine — yet. Graphic: AI Frontier Post.

What the valuation is really pricing

A $40 billion valuation is not a reward for results — it is a bet on a chain that hasn't been completed. No AI-designed medicine has yet reached the market, and clinical trials remain the brutal filter every AI drug-discovery company must pass. The company's own reported work — computationally designed molecules tested in the lab, preclinical programs — is company-reported, not independent proof. The counter-view making the rounds: the sector keeps raising larger checks before the first proof of clinical efficacy arrives, and a $50 billion figure would make Isomorphic worth more than most mid-cap pharmaceutical companies on the strength of models alone.

Still, the demand side is real and growing. OpenAI recently released a model aimed at life-sciences research, and Alphabet's other big bets show the playbook: Waymo raised $16 billion at a $126 billion valuation earlier this year. If the talks close anywhere near the reported numbers, Isomorphic Labs would become one of the most valuable AI companies ever to raise money on a promise of curing disease rather than selling software.

Sources: RuntimeWire (Oct. 8, 2026, citing Bloomberg Technology); Bloomberg Law (Oct. 8, 2026, carrying the Bloomberg report); The Hindu BusinessLine (May 2026, on the $2.1B Series B); AInvest (on the March 2025 $600M round).